MCID: OVR104
MIFTS: 35

Ovarian Melanoma

Categories: Cancer diseases, Endocrine diseases, Reproductive diseases, Skin diseases

Aliases & Classifications for Ovarian Melanoma

MalaCards integrated aliases for Ovarian Melanoma:

Name: Ovarian Melanoma 12 15

Classifications:



External Ids:

Disease Ontology 12 DOID:0050928

Summaries for Ovarian Melanoma

Disease Ontology : 12 An ovarian cancer that has material basis in melanoctyes.

MalaCards based summary : Ovarian Melanoma is related to melanoma and senile angioma. An important gene associated with Ovarian Melanoma is MAP2K1 (Mitogen-Activated Protein Kinase Kinase 1), and among its related pathways/superpathways are Integrin Pathway and Cytokine Signaling in Immune system. The drugs Antibodies and Immunologic Factors have been mentioned in the context of this disorder. Affiliated tissues include ovary, breast and colon, and related phenotypes are cardiovascular system and digestive/alimentary

Related Diseases for Ovarian Melanoma

Diseases related to Ovarian Melanoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 85)
# Related Disease Score Top Affiliating Genes
1 melanoma 29.5 PTEN NRAS MLANA MAP2K1
2 senile angioma 10.4 MAP2K1 KIT
3 acral lentiginous melanoma 10.4 NRAS KIT
4 malignant spindle cell melanoma 10.4 NRAS KIT
5 giant congenital nevus 10.3 NRAS HRAS
6 mixed type thymoma 10.3 PTEN KIT
7 benign struma ovarii 10.3 NRAS HRAS
8 schimmelpenning-feuerstein-mims syndrome 10.3 NRAS HRAS
9 melanomatosis 10.3 NRAS HRAS
10 malignant conjunctival melanoma 10.3 NRAS HRAS
11 congenital mesoblastic nephroma 10.3 NRAS KIT
12 ovarian fibrothecoma 10.3 KIT CALB2
13 prostate small cell carcinoma 10.3 PTEN KIT
14 marcus gunn phenomenon 10.3 NRAS HRAS
15 thymoma, familial 10.3 KIT HRAS
16 malignant struma ovarii 10.3 NRAS HRAS
17 nodular malignant melanoma 10.3 NRAS HRAS
18 aggressive digital papillary adenocarcinoma 10.3 KIT HRAS
19 fetal adenoma 10.3 NRAS HRAS
20 malignant leydig cell tumor 10.3 KIT CALB2
21 lung adenoid cystic carcinoma 10.3 KIT HRAS
22 meningeal melanomatosis 10.2 NRAS HRAS
23 mucosal melanoma 10.2 NRAS KIT
24 rete testis adenocarcinoma 10.2 KIT CALB2
25 melanocytic nevus syndrome, congenital 10.2 NRAS HRAS
26 mixed germ cell-sex cord neoplasm 10.2 KIT CALB2
27 neurogenic bowel 10.2 KIT CALB2
28 rete testis neoplasm 10.2 KIT CALB2
29 malignant anus melanoma 10.2 MLANA KIT
30 functional colonic disease 10.2 KIT CALB2
31 breast angiosarcoma 10.2 MLANA KIT
32 liver angiosarcoma 10.1 NRAS HRAS
33 costello syndrome 10.1 MAP2K1 HRAS
34 undifferentiated pleomorphic sarcoma 10.1 MLANA KIT
35 mixed cell type cancer 10.1 KIT HRAS
36 meningeal melanocytoma 10.1 NRAS MLANA
37 colonic pseudo-obstruction 10.1 KIT CALB2
38 acneiform dermatitis 10.0 NRAS MAP2K1 HRAS
39 small cell carcinoma 10.0 SMARCA4 PTEN KIT
40 pancreatic mucinous cystadenoma 10.0 HRAS CALB2
41 deep leiomyoma 10.0 KIT CALD1
42 dysgerminoma of ovary 10.0 KIT CALB2
43 core binding factor acute myeloid leukemia 10.0 NRAS KIT HRAS
44 myeloid leukemia 10.0 NRAS KIT HRAS
45 angiomyoma 9.9 KIT CALD1
46 pulmonic stenosis 9.9 MAP2K1 HRAS
47 ovarian brenner tumor 9.9 KIT CALB2
48 mesenchymal cell neoplasm 9.9 KIT CALD1
49 thyroid cancer, nonmedullary, 2 9.9 PTEN NRAS HRAS
50 carcinosarcoma 9.9 PTEN KIT HRAS

Graphical network of the top 20 diseases related to Ovarian Melanoma:



Diseases related to Ovarian Melanoma

Symptoms & Phenotypes for Ovarian Melanoma

MGI Mouse Phenotypes related to Ovarian Melanoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.93 HRAS KIT MAP2K1 NRAS PTEN SMARCA4
2 digestive/alimentary MP:0005381 9.88 HRAS KIT MAP2K1 NRAS PTEN SMARCA4
3 integument MP:0010771 9.87 HRAS KIT MAP2K1 MLANA NRAS PTEN
4 endocrine/exocrine gland MP:0005379 9.85 HRAS KIT MAP2K1 NRAS PTEN SMARCA4
5 craniofacial MP:0005382 9.83 HRAS KIT MAP2K1 NRAS SMARCA4
6 neoplasm MP:0002006 9.73 HRAS KIT MAP2K1 NRAS PTEN SMARCA4
7 normal MP:0002873 9.7 CALB2 HRAS KIT MAP2K1 NRAS PTEN
8 pigmentation MP:0001186 9.26 KIT MLANA NRAS PTEN
9 skeleton MP:0005390 9.1 HRAS KIT MAP2K1 NRAS PTEN SMARCA4

Drugs & Therapeutics for Ovarian Melanoma

Drugs for Ovarian Melanoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):


# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Antibodies Phase 1
2 Immunologic Factors Phase 1
3 Antineoplastic Agents, Immunological Phase 1
4 Antibodies, Monoclonal Phase 1
5 Immunoglobulins Phase 1

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 A Study of the Safety, Tolerability, and Pharmacokinetics of MORAb-004, a Humanized Monoclonal Antibody, in Subjects With Solid Tumors Completed NCT00847054 Phase 1 MORAb-004 (monoclonal antibody to TEM1)

Search NIH Clinical Center for Ovarian Melanoma

Genetic Tests for Ovarian Melanoma

Anatomical Context for Ovarian Melanoma

MalaCards organs/tissues related to Ovarian Melanoma:

41
Ovary, Breast, Colon, Prostate, Testes

Publications for Ovarian Melanoma

Articles related to Ovarian Melanoma:

(show all 45)
# Title Authors PMID Year
1
Preclinical testing of 5-amino-1-((1R,2S,3S,4R)-2,3-dihydroxy-4-methylcyclopentyl)-1H-imidazole-4-carboxamide: a potent protein kinase C-ι inhibitor as a potential prostate carcinoma therapeutic. 38
30204596 2019
2
Overexpression of TBX3 transcription factor as a potential diagnostic marker for breast cancer. 38
30655984 2019
3
A rare melanoma feature with primary ovarian origin: a case report and the literature review. 38
29564322 2018
4
Title ultrasound features of ovarian melanoma metastases: The "Golf ball" aspect. 38
29198556 2018
5
In Defense of Progesterone: A Review of the Literature. 38
29055286 2017
6
Loss of SMARCA4 Expression Is Both Sensitive and Specific for the Diagnosis of Small Cell Carcinoma of Ovary, Hypercalcemic Type. 38
26645725 2016
7
Synthesis, biological evaluation, drug-likeness, and in silico screening of novel benzylidene-hydrazone analogues as small molecule anticancer agents. 38
26694484 2016
8
Activity-Based Protein Profiling of Oncogene-Driven Changes in Metabolism Reveals Broad Dysregulation of PAFAH1B2 and 1B3 in Cancer. 38
25945974 2015
9
KRAS Genomic Status Predicts the Sensitivity of Ovarian Cancer Cells to Decitabine. 38
25968887 2015
10
Malignant melanoma arising in an ovarian mature cystic teratoma - a rare entity. 38
26023561 2015
11
Primary gynecologic melanoma: A report of two unusual cases. 38
26076092 2015
12
Expression of breast cancer metastasis suppressor-1, BRMS-1, in human breast cancer and the biological impact of BRMS-1 on the migration of breast cancer cells. 38
24596389 2014
13
Metastatic malignant ovarian melanoma--a case report. 38
23607194 2013
14
Ovarian melanoma complicating pregnancy achieved by in-vitro fertilisation. 38
23259897 2013
15
Ukrain, a plant derived semi-synthetic compound, exerts antitumor effects against murine and human breast cancer and induce protective antitumor immunity in mice. 38
23302993 2012
16
Effects of individual-level socioeconomic factors on racial disparities in cancer treatment and survival: findings from the National Longitudinal Mortality Study, 1979-2003. 38
21264829 2011
17
Metastatic ovarian malignant melanoma with no obvious primary. 38
24591988 2011
18
Ovarian malignant melanoma: a clinicopathologic study of 5 cases. 38
18794169 2010
19
Malignant ovarian melanoma with extensive pelvic and peritoneal metastasis: a case report and literature review. 38
20346227 2010
20
Mutations of the KIT gene and loss of heterozygosity of the PTEN region in a primary malignant melanoma arising from a mature cystic teratoma of the ovary. 38
19264228 2009
21
Identification of human pancreatic cancer stem cells. 38
19582426 2009
22
GTI-2501, an antisense agent targeting R1, the large subunit of human ribonucleotide reductase, shows potent anti-tumor activity against a variety of tumors. 38
16391803 2006
23
Malignant melanoma and fibrothecoma--an ovarian mixed tumor. 38
16033067 2005
24
Ovarian cystic teratoma with primary epithelial cell melanoma. 38
15755005 2005
25
Carbonic anhydrase inhibitors: sulfonamides as antitumor agents? 38
11310605 2001
26
Arylsulfonyl-N,N-dialkyl-dithiocarbamates as tumor cell growth inhibitors: novel agents targeting beta-tubulin? 38
11496835 2001
27
4-toluenesulfonylureido derivatives of amines, amino acids and dipeptides: a novel class of potential antitumor agents. 38
11033076 2000
28
Carbonic anhydrase inhibitors--Part 94. 1,3,4-thiadiazole-2-sulfonamidederivatives as antitumor agents? 38
11203012 2000
29
Arylsulfonyl-N,N-diethyl-dithiocarbamates: a novel class of antitumor agents. 38
10969992 2000
30
Carbonic anhydrase inhibitors: synthesis of N-morpholylthiocarbonylsulfenylamino aromatic/heterocyclic sulfonamides and their interaction with isozymes I, II and IV. 38
10843231 2000
31
Carbonic anhydrase inhibitors: aromatic sulfonamides and disulfonamides act as efficient tumor growth inhibitors. 38
11140614 2000
32
Malignant melanoma metastatic to the ovary: presentation and radiological characteristics. 38
9600825 1998
33
Malignant melanoma arising in mature ovarian cystic teratoma (dermoid cyst). Report of two cases and literature analysis. 38
8886884 1996
34
Resistance mechanisms determining the in vitro sensitivity to paclitaxel of tumour cells cultured from patients with ovarian cancer. 38
7718330 1995
35
Malignant melanoma of the female genital system. 38
8181579 1994
36
[Metastatic ovarian melanoma in a 26-year-old patient]. 38
7941811 1994
37
Primary ovarian melanoma arising in a dermoid stage IIIc: long-term disease-free survival with aggressive surgery and platinum therapy. 38
8462906 1993
38
Multidrug-resistant phenotype of disease-oriented panels of human tumor cell lines used for anticancer drug screening. 38
1350507 1992
39
Malignant melanoma arising in ovarian cystic teratoma. 38
1959792 1991
40
Malignant melanoma presenting as a unilateral ovarian neoplasm. 38
2424811 1986
41
Comparative studies of ampligen (mismatched double-stranded RNA) and interferons. 38
2418160 1985
42
Ovarian melanoma. An interesting case. 38
6144596 1984
43
Malignant metastatic ovarian melanoma: a case report. 38
7347681 1981
44
Selection of malignant melanoma variant cell lines for ovary colonization. 38
544929 1979
45
A compound nevus in a benign cystic teratoma of the ovary. 38
937274 1976

Variations for Ovarian Melanoma

Expression for Ovarian Melanoma

Search GEO for disease gene expression data for Ovarian Melanoma.

Pathways for Ovarian Melanoma

Pathways related to Ovarian Melanoma according to GeneCards Suite gene sharing:

(show top 50) (show all 95)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.29 PTEN NRAS MAP2K1 HRAS CALD1
2
Show member pathways
13.25 SMARCA4 NRAS MAP2K1 KIT HRAS
3
Show member pathways
13.21 PTEN NRAS MAP2K1 KIT HRAS
4
Show member pathways
12.95 NRAS MAP2K1 KIT HRAS
5
Show member pathways
12.94 PTEN NRAS MAP2K1 KIT HRAS
6
Show member pathways
12.86 PTEN NRAS MAP2K1 HRAS
7
Show member pathways
12.86 PTEN NRAS MAP2K1 KIT HRAS
8
Show member pathways
12.85 PTEN NRAS MAP2K1 HRAS
9
Show member pathways
12.83 PTEN NRAS MAP2K1 HRAS
10
Show member pathways
12.82 PTEN NRAS MAP2K1 HRAS
11
Show member pathways
12.81 PTEN NRAS MAP2K1 HRAS
12
Show member pathways
12.8 NRAS MAP2K1 KIT HRAS CALD1
13
Show member pathways
12.78 PTEN NRAS MAP2K1 HRAS
14
Show member pathways
12.73 PTEN NRAS MAP2K1 KIT HRAS
15 12.68 PTEN NRAS MAP2K1 KIT HRAS
16 12.67 NRAS MAP2K1 KIT HRAS
17
Show member pathways
12.64 NRAS MAP2K1 KIT HRAS
18
Show member pathways
12.64 PTEN NRAS KIT HRAS
19
Show member pathways
12.61 PTEN NRAS MAP2K1 HRAS
20
Show member pathways
12.6 PTEN NRAS MAP2K1 HRAS
21
Show member pathways
12.57 PTEN NRAS MAP2K1 HRAS
22
Show member pathways
12.5 NRAS MAP2K1 HRAS
23
Show member pathways
12.49 PTEN NRAS MAP2K1 HRAS
24
Show member pathways
12.48 NRAS MAP2K1 HRAS
25 12.43 PTEN NRAS MAP2K1 HRAS
26
Show member pathways
12.4 PTEN NRAS MAP2K1 HRAS
27
Show member pathways
12.38 PTEN NRAS MAP2K1 HRAS
28
Show member pathways
12.36 NRAS MAP2K1 HRAS
29
Show member pathways
12.36 NRAS MAP2K1 HRAS
30
Show member pathways
12.34 NRAS MAP2K1 HRAS
31
Show member pathways
12.32 PTEN MAP2K1 HRAS
32
Show member pathways
12.31 NRAS MAP2K1 KIT HRAS
33
Show member pathways
12.29 NRAS MAP2K1 KIT HRAS
34
Show member pathways
12.29 PTEN NRAS MAP2K1 HRAS
35
Show member pathways
12.27 NRAS MAP2K1 HRAS
36 12.24 NRAS MAP2K1 HRAS
37
Show member pathways
12.23 NRAS MAP2K1 HRAS
38
Show member pathways
12.2 PTEN NRAS MAP2K1 HRAS
39
Show member pathways
12.19 NRAS MAP2K1 HRAS
40
Show member pathways
12.14 NRAS MAP2K1 HRAS CALD1
41
Show member pathways
12.14 NRAS MAP2K1 HRAS
42
Show member pathways
12.13 NRAS MAP2K1 HRAS
43
Show member pathways
12.12 NRAS MAP2K1 HRAS
44 12.11 PTEN MAP2K1 HRAS
45
Show member pathways
12.1 NRAS MAP2K1 HRAS
46
Show member pathways
12.1 PTEN NRAS MAP2K1 HRAS
47
Show member pathways
12.1 SMARCA4 PTEN NRAS MAP2K1 KIT HRAS
48
Show member pathways
12.09 PTEN NRAS MAP2K1 HRAS
49
Show member pathways
12.08 NRAS MAP2K1 HRAS
50 12.07 PTEN NRAS HRAS

GO Terms for Ovarian Melanoma

Biological processes related to Ovarian Melanoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.62 PTEN MAP2K1 KIT HRAS
2 positive regulation of DNA-binding transcription factor activity GO:0051091 9.43 SMARCA4 PTEN KIT
3 cellular senescence GO:0090398 9.4 MAP2K1 HRAS
4 positive regulation of phospholipase C activity GO:0010863 9.37 KIT HRAS
5 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.26 PTEN MAP2K1 KIT HRAS
6 regulation of axon regeneration GO:0048679 9.16 PTEN MAP2K1
7 MAPK cascade GO:0000165 8.92 NRAS MAP2K1 KIT HRAS

Molecular functions related to Ovarian Melanoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleotide binding GO:0000166 9.02 SMARCA4 NRAS MAP2K1 KIT HRAS

Sources for Ovarian Melanoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....